Janux Therapeutics, Inc.
JANX
$13.79
-$0.26-1.85%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -58.02% | 13.35% | -468.18% | -59.27% | -71.93% |
| Total Depreciation and Amortization | -8.59% | -1.76% | 6.92% | -2.44% | -3.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 80.23% | -64.60% | 106.68% | 68.86% | 37.24% |
| Change in Net Operating Assets | -785.51% | -49.06% | 151.01% | 88.40% | 68.52% |
| Cash from Operations | -70.65% | -476.24% | -137.63% | -14.74% | -68.92% |
| Capital Expenditure | -152.38% | -272.00% | -397.89% | -88.32% | 91.84% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -12.71% | -33.86% | 101.07% | -199.48% | 191.87% |
| Cash from Investing | -12.92% | -34.46% | 100.82% | -199.28% | 205.01% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.24% | -70.10% | -65.50% | -99.72% | 46,428.28% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.24% | -70.10% | -65.50% | -99.83% | 46,428.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -99.02% | -133.55% | 89.25% | -284.33% | 19,571.26% |